echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: In patients with chronic migraine and medication overuse (CMMO), maintaining migraine preventive medication use is not inferior to limiting/switching migraine preventive medication use!

    Neurology: In patients with chronic migraine and medication overuse (CMMO), maintaining migraine preventive medication use is not inferior to limiting/switching migraine preventive medication use!

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Eight percent of the migraine population suffers from chronic migraine (CM) , defined as 15 headache days per month, which includes ≥8 days/month with symptoms that meet the diagnostic criteria for migraine


    Previous studies of CM with MO (CMMO) have provided evidence of the effectiveness of two patient-centered treatment strategies: migraine preventive medications that stop overuse and migraine preventive


    We sought to determine whether migraine prophylaxis that did not switch or limit the frequency of overmedication was comparable to migraine prophylaxis that switched from overmedication to the use of alternative medications <2 days per week



    • A random sample of 720 participants, with a mean age of 44 years (SD 13 years), was 87.


      Using a reduction in the number of days with moderate to severe headaches as a consequence of CMMO treatment concerns, migraine prophylaxis without switching or limiting symptomatic medication was not inferior to migraine prophylaxis with switching to a different symptomatic medication (up to 2 days per week)


      Source: Schwedt T, Hentz J, Sahai-Srivastava S, et al.


      Schwedt T, Hentz J, Sahai-Srivastava S, et al.
      Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial [published online ahead of print, 2022 Feb 15].
      Neurology.
      2022;10.
      1212 /WNL.
      0000000000200117.
      doi:10.
      1212/WNL.
      0000000000200117Leave

      a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.